Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. - Wikidata - awgldk - TriplyDB

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.

http://www.wikidata.org/entity/Q41966195

about

Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.The clinical development of obinutuzumab for the treatment of follicular lymphoma.Shifting Focus in the Therapeutics of Immunobullous Disease.Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor.Obinutuzumab: first global approval.A combinatorial mutagenesis approach for functional epitope mapping on phage-displayed target antigen: application to antibodies against epidermal growth factor.Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.High-throughput epitope binning assays on label-free array-based biosensors can yield exquisite epitope discrimination that facilitates the selection of monoclonal antibodies with functional activity.Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.CD30 as a therapeutic target for lymphoma.Update on obinutuzumab in the treatment of B-cell malignancies.Three major uncertainties in the antibody therapy of cancer.Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.How to successfully patent therapeutic antibodies.Ofatumumab in the treatment of non-Hodgkin's lymphomas.Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.Advancing drug delivery systems for the treatment of multiple sclerosis.Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells.Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro.Targeting B cells in treatment of autoimmunity.Anti-CD20 monoclonal antibodies in multiple sclerosis.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.Ocrelizumab and Other CD20(+) B-Cell-Depleting Therapies in Multiple Sclerosis.Opsoclonus-Myoclonus Syndrome during Rituximab Treatment for Autoimmune Autonomic Ganglionopathy.Monoclonal antibodies targeting CD20.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.

P2860

Q26751002-7C371F6E-EE70-447B-984C-883614C469B5 Q26781163-59F5A531-6990-4BF9-92F7-2C87DCAA9121 Q26801292-93C53B3A-6F93-4BEE-A0A5-EA4A0E94C958 Q26849243-93386947-4860-445E-B1E4-E5215A344A85 Q33416524-C9147704-99C3-42D1-879F-732256443F77 Q33565265-B2F9E813-F986-4783-B2A5-7CFC44B6BEA9 Q33737974-FB5C5872-D333-44D7-A438-61D7EF090AC2 Q34223866-F5A16206-6115-4804-A9C8-D205D2250228 Q34391958-DEC02B34-BB39-4AD9-AD76-FFA33B566B30 Q35109650-365A4BDA-20CF-4167-9F2B-954F05533F80 Q35110582-506CA4A8-587B-42CE-9C12-372136A5ACA6 Q35126754-00678F43-5EBA-42D7-9D44-F9A0106E1C80 Q35918945-4FF6FE8F-6DB9-41DE-BEA2-62E999FDA76E Q37380415-B978F55C-2DB9-482D-A09C-638513CB89E8 Q37672472-107AA3FC-54B9-4EA2-9AAE-799E6C417F6E Q37741570-389D1756-A307-4BB6-8FB1-6B8DD9707E10 Q38138482-F7957ADB-CCDE-47CB-90D3-E68AAB1D7A4F Q38246230-2DDB4644-7442-4D45-83B2-C1E241DA6C6C Q38255786-0F2DDD0C-1C2F-40B7-903C-791E097A34F7 Q38317353-55C3BED8-1833-404E-AE6D-6D1C62F160CD Q38329651-082F1864-FBE3-418E-A568-56CF122E0DC9 Q38516077-29BACF97-8A2A-4273-8B91-A1AB26708462 Q38537523-3A56E352-E3C4-4C0A-B09F-4FD2A9249717 Q38542034-6A42E472-14CE-464E-A014-E3427A4C99CE Q38601727-89217E92-EFDA-415C-983A-DF3C0C6CFCB7 Q38609620-F327D85C-5276-4919-AE98-711D68AFBEF1 Q38665518-0A98C7B9-A3F7-4499-855A-C154E84F6D92 Q38711882-86569E49-9837-4686-BC85-289F1CF00076 Q38759420-E5B57A1E-6175-4FB9-9EF1-BEAD4DC96896 Q38782706-7250A5A7-A18C-4876-B16D-DB72029B7BF5 Q38808291-13CE51A9-AF9F-4B18-B17F-9923D1059A36 Q38975656-720B7DD9-A477-49A4-9696-8094B922DD7C Q38975695-7D630F74-88BA-4B05-92CE-16EB33DCC69F Q39018189-CA660BB0-02F1-424E-9A0D-792A57963CC8 Q39279968-FE0C0988-9343-4B55-B7DD-E998B42A2A92 Q39427711-F88C4EEE-ED5C-48C1-A327-6C699B963137 Q40993874-0ADF6C0F-1BE8-459C-888C-1787B54731A0 Q42906640-840EEA3E-2255-49A6-9252-B06C39C55762 Q47221234-F81C3DFD-FDCF-484D-B3D1-403FC7103A49 Q47688545-4925F8D7-8CA0-429B-8677-7E66460431CD

P2860

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.

http://www.wikidata.org/entity/Q41966195

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Epitope interactions of monocl ...... ship to functional properties.

@en

type

label

Epitope interactions of monocl ...... ship to functional properties.

@en

prefLabel

Epitope interactions of monocl ...... ship to functional properties.

@en

P1433

Q41966195-C1E8FC58-3DDD-423C-B7C9-5473B7F72FB9

P1476

Q41966195-F342FD65-AAB9-4D08-BCB2-7160A5E5067D

P2093

Q41966195-029B10FE-F45E-4380-93B0-6E20F90AA7DA

Q41966195-1492363C-0090-43C1-A5EA-92B6A783AEEA

Q41966195-1A9AD656-C178-4329-85ED-EA358C2F1E88

Q41966195-4ED5F037-4D83-41CF-880A-74B24CD2D684

Q41966195-55B06BCD-EBC7-4FCE-B999-30511B8CE9F0

Q41966195-86A63C75-6EBE-4EB1-BC3D-1BBFC014B607

Q41966195-C544842C-523F-4A2D-BCC7-1E9F762D3C44

Q41966195-FAE0A690-E7A9-4723-B3A7-33AA9D462960

P2860

Q41966195-036A0EA6-05C0-4632-9508-B51CD57CC77D

Q41966195-061A8BCD-D955-4723-B78F-01E9370FFDD2

Q41966195-074BE229-8FC9-4B34-B821-FC9D23D01CAD

Q41966195-099DEFF0-2A93-4336-8629-93DA04CDAC7A

Q41966195-09A59459-8587-4132-9127-82742C7337EF

Q41966195-0D622468-574A-46E0-A6A3-CE2A40E066E8

Q41966195-0FE768AD-1E40-46BC-9E9C-20D0A2045D33

Q41966195-146EDE33-3052-4AC8-A304-3150AD343CE4

Q41966195-1555587E-35AB-4873-A498-DBFC2F2D9A60

Q41966195-17AFAE9C-D3BB-44EE-9592-E57CD325AA8C

P304

Q41966195-CF8F0023-D669-4879-9FFA-6A7FC34E8A0B

P31

Q41966195-53F59DDE-84BB-4E4E-AA09-152A47833725

Q41966195-8e40226b-9354-43ac-a696-09b63de22d65

P356

Q41966195-B4B37508-FA1A-4EA1-B3DF-57F8652B9D58

P433

Q41966195-38A93D0E-43CB-421E-B112-466E261C05B0

P478

Q41966195-281DD652-E9D8-438A-B86B-030093BE28AB

P50

Q41966195-AA774FE6-49C8-4B83-919A-AB580FDA556E

P577

Q41966195-E6E66B1E-DE6B-47E3-AAF6-3A130CD90AA7

P5875

Q41966195-3166AB89-FC48-47B6-AC0E-FAD8442DA41F

P698

Q41966195-3E973140-9408-41B1-B64A-C2411E496FF5

P921

Q41966195-F3EBA123-214B-4F36-94AA-9D2FE2B38BF7

P932

Q41966195-ACC1C049-FE70-43A7-B6BA-EBAFC8A0A855

P356

P1433

Monoclonal Antibodies

P1476

Epitope interactions of monocl ...... ship to functional properties.

@en

P2093

Alfred Lammens

http://www.w3.org/2001/XMLSchema#string

Christian Klein

http://www.w3.org/2001/XMLSchema#string

Ekkehard Mössner

http://www.w3.org/2001/XMLSchema#string

Gerhard Niederfellner

http://www.w3.org/2001/XMLSchema#string

Guy Georges

http://www.w3.org/2001/XMLSchema#string

Manfred Schwaiger

http://www.w3.org/2001/XMLSchema#string

Pablo Umaña

http://www.w3.org/2001/XMLSchema#string

Wolfgang Schäfer

http://www.w3.org/2001/XMLSchema#string

P2860

Rituximab as maintenance therapy for patients with follicular lymphoma

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide

Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

The biology of CD20 and its potential as a target for mAb therapy

Role of Maintenance Rituximab (Rituxan) Therapy In the Treatment of Follicular Lymphoma

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells

P304

22-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.22771

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Karl-Peter Hopfner

P577

2012-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233848516

http://www.w3.org/2001/XMLSchema#string

P698

23211638

http://www.w3.org/2001/XMLSchema#string

P921

P932

3564883

http://www.w3.org/2001/XMLSchema#string